Nature Biotechnology, Published online: 15 April 2026; doi:10.1038/s41587-026-03077-5
Inducible base editors enhance cancer genomic screens in vivo.
Structure-centric searching enables global mapping of the public metabolome
Nature Biotechnology, Published online: 15 April 2026; doi:10.1038/s41587-026-03082-8
StructureMASST enables pan-repository MS/MS searches using a chemical name or structure.
Closing the gap on antifungal resistance
Nature Medicine, Published online: 15 April 2026; doi:10.1038/s41591-026-04334-5
Drug-resistant fungal disease must be addressed in the 2026 update to the Global Action Plan on Antimicrobial Resistance
Rapid expansion of genotype D1.1 A(H5N1) influenza viruses in wild birds across North America during the 2024 migratory season
Nature Medicine, Published online: 15 April 2026; doi:10.1038/s41591-026-04300-1
Using active and passive genomic surveillance, researchers observed the rapid spread of high pathogenicity avian influenza H5N1 D1.1 viruses in wild birds during the 2024 migratory season, which coincided with detection in humans, but did not identify mammalian adaptive markers in viruses from wild birds.
Proteomic risk score for early prediction of kidney disease progression in individuals with APOL1 high-risk genotypes
Nature Medicine, Published online: 15 April 2026; doi:10.1038/s41591-026-04337-2
For individuals with APOL1 high-risk genotypes, which are enriched in individuals of African ancestry, a nine-protein proteomic risk score enables early prediction of kidney disease progression and may, thereby, enable early intervention.
An acetylated Tau-174 CSF biomarker discriminates between TDP-43 and tau pathology in patients with frontotemporal lobar degeneration
Nature Medicine, Published online: 15 April 2026; doi:10.1038/s41591-026-04341-6
A new cerebrospinal fluid biomarker, AcTau174, was elevated in frontotemporal lobar degeneration with TAR DNA-binding protein (FTLD-TDP), distinguishing this pathology from FTLD-Tau, and was associated with disease severity and progression in FTLD-TDP.
Amyloid-β-driven glymphatic dysfunction in Alzheimer’s disease model mice is driven by Ca2+-mediated increases in astrocytic cholesterol
Nature Neuroscience, Published online: 15 April 2026; doi:10.1038/s41593-026-02261-9
This study uncovers how amyloid-β boosts astrocyte calcium activity, increasing cholesterol and disrupting brain waste clearance in an Alzheimer’s disease mouse model. Targeting astrocyte calcium or cholesterol restores clearance and improves cognition.
<![CDATA[How clinicians choose TRD treatments: patient preference, esketamine vs brain stimulation, and fast-acting glutamate options that improve function.]]>
<![CDATA[Experts explain which narcolepsy meds suit kids—oxybates and pitolisant approvals, stimulant side effects, and key heart-safety checks.]]>
<![CDATA[Learn how DEA scheduling shapes narcolepsy treatment choices, and why emerging orexin agonists may transform daytime sleepiness and cataplexy care.]]>